KVUE Kenvue

FY2024 10-K
Filed: Feb 24, 2025
Health Care
Perfumes, Cosmetics & Other Toilet PreparationsSEC EDGAR

Kenvue (KVUE) filed its fiscal year 2024 10-K annual report with the SEC on Feb 24, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Management Discussion & Analysis

  • Operating cash flow $1.8B down $1.4B YoY from $3.2B in fiscal 2023, decline driven by working capital changes
  • Financing cash outflow $1.6B in fiscal 2024, included $1.55B dividends and $235M share repurchases; repurchased 10.86M shares for $235M
+3 more insights

Risk Factors

  • Talc-related litigation risk for Johnson’s® Baby Powder sold outside US/Canada, with talc-based powder discontinued globally in 2023
  • Global operations exposed to foreign currency fluctuations and geopolitical conflicts impacting supply and costs
+3 more insights

Financial Summary
XBRL

Revenue

$15.5B

Net Income

$1.0B

Gross Margin

58.0%

Operating Margin

11.9%

Net Margin

6.7%

ROE

10.7%

Total Assets

$25.6B

EPS (Diluted)

$0.54

Operating Cash Flow

$1.8B

Source: XBRL data from Kenvue FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Kenvue Annual Reports

Get deeper insights on Kenvue

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available